GDA

Across TCGA pan-cancer cohorts, GDA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GDA data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GDA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GDA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where GDA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.886	0.526	.002	76	view →
PDAC	DFS	Quartile	III,IV	0.965	0.464	<.001	71	view →
LUAD	OS	Median	All	0.848	0.356	.026	6	view →
UCEC	DFS	Median	All	1.000	0.936	.022	6	view →
LSCC	OS	Quartile	All	0.786	0.977	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GDA–CCRCC (DFS)

Open the CCRCC breakdown →